What question did this study set out to answer?

This analysis aims to assess the trends and status of literature regarding immune-related adverse events in lung cancer from 2016 to 2025.

June 6, 2026Frontiers in ImmunologyOpen Access

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

View Full Paper

Ask AI

Bookmark

Authors

BGBing GuoQingdao University GZG ZHANGQingdao University SSShengpeng SangQingdao University

Discussion

Member takes

Implication

Bibliometric analysis reviews publication trends and research patterns of immune-related adverse events in lung cancer, highlighting key findings and areas for future investigation.

Key Points

This analysis aims to assess the trends and status of literature regarding immune-related adverse events in lung cancer from 2016 to 2025.
Analyzed 1,792 records from the Web of Science Core Collection
Utilized Bibliometrix and CiteSpace for visualizations
Supplemented findings with clinical-topic mapping from PubMed records.
Annual publications in this field increased, showing three phases: initial, rapid increase, and stable development.
China ranked first with 626 publications; however, the US had higher centrality in international collaboration.
Word analysis identified shifts in research focus, including recurrent disease and specific irAE topics.

Cite This Study

Guo et al. (2026) studied this question.

synapsesocial.com/papers/6a23b80771a5da9775e7463e https://doi.org/10.3389/fimmu.2026.1846212

View Full Paper

Ask AI

Bookmark

Implication

Bibliometric analysis reviews publication trends and research patterns of immune-related adverse events in lung cancer, highlighting key findings and areas for future investigation.

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

Discussion

Member takes

Implication

Key Points

Cite This Study

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider